Subscribe to RSS
DOI: 10.1055/s-0043-57033
2022 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards
Welcome to the latest of our Eberhard F. Mammen award announcements. As noted many times previously, Thieme, the publisher of Seminars in Thrombosis and Hemostasis (STH), has created the “Eberhard F. Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades (see [Table 1] for relevant references). These awards began in 2009 under two categories; the current award details and conditions are as follows:
-
Most popular article awards: Awarded to the authors of the most popular articles published in STH in the preceding 2 years as captured in the preceding year. The awards are determined by the editor in chief on the basis of user statistics from Thieme e-Journals. Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories—one for “Free Access” articles and another for a “General Category.” There are two major cash prizes of U.S. $1,000 for each category. In addition, winners of the “General Category” awards are granted “Free Access” status for these articles thereafter.
-
Young investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen (up to six cash prizes of U.S. $1,000 in any year). There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. In general, previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the senior editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given the ongoing COVID-19 pandemic, many international congresses have become virtual meetings, and accordingly, virtual meeting presentations can also be considered for the award.
Further details of the awards and the award winners are posted online (https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077), and previous award winner announcements are also available in print (see [Table 1] for a listing of relevant editorials published in this journal as related to the initiation of the Eberhard F. Mammen awards, as well as previous award announcements); these publications are also available for free download from the journal website: https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077.
The winners of the 2022 Eberhard F. Mammen awards for the most popular articles from STH for the period of 2020–2021 inclusive were announced in an earlier issue of the journal,[1] as were the 2023 Eberhard F. Mammen awards for the most popular articles from STH for the period of 2021–2022 inclusive.[2] It is therefore with great pleasure that we would like to announce the winners of the latest round of Young Investigator awards.
As mentioned earlier, the Young Investigator Awards represent winners of the best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting (virtual meetings permissible) on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr. Mammen. There are additional considerations, given that the nominees' presentations are not necessarily seen by all of the possible award nominators, being drawn from the broader editorial team of the journal as well as potentially from outside the editorial team, nor necessarily seen by all the voting team (comprising the senior editors of the journal). The latest winners are identified later, with a running list of previous awardees, and the resulting publications in the journal, given in [Table 2]. The latest awardees derived from recent meetings of the International Society on Thrombosis and Haemostasis (ISTH) and the American Heart Association (AHA).
As often occurs with these awards, the current crop of winners reflects a variety of “Young Investigators” at various stages of their careers. Some awardees are just starting out on their journey in science or medicine, while others are better established in their careers and crossing over into the next phase of their life where they will soon no longer be called “young” investigators.
Rayna Anjis ([Fig. 2]) is the youngest of our award recipients, and is currently finishing her PhD at the department of Thrombosis and Hemostasis and Clinical Epidemiology at the Leiden University Medical Center (LUMC) in the Netherlands. Supervised by Prof. Henri Versteeg and Prof. Suzanne Cannegieter, her PhD research focused on the link between cancer and thrombosis, approaching this from both a translational and epidemiological setting. Furthermore, she is in training to become a clinical epidemiologist and is a PhD representative board member of the Dutch Society for Thrombosis and Hemostasis (NVTH) since 2020.
Aisling Rehill ([Fig. 3]) is another of the younger awardees. She completed her PhD in 2021 in the Irish Centre of Vascular Biology, School of Pharmacy and Biomolecular Sciences at the Royal College of Surgeons in Ireland, Dublin, under the supervision of Dr. Roger Preston. Her thesis research focused on optimizing methods for measuring dysregulated hemostasis. Furthermore, she examined the role of myeloid cells in modulating hemostasis and identified a key role for glycolysis in modulating myeloid cell hemostatic function. Aisling currently works as a postdoctoral researcher in the Preston Group, investigating how innate immune training can alter myeloid cell hemostatic function. This award was based on an oral communication presented at the ISTH meeting titled “Metabolic Reprogramming Is Essential for Myeloid Cell-Dependent Haemostatic Activity.”
Harvey Roweth ([Fig. 4]) is the last of our younger awardees. He is a post-doctoral research fellow working at Brigham and Women's Hospital and Harvard Institutes of Medicine. His research focuses on understanding the complex contributions of platelets and megakaryocytes to both the tumor microenvironment and in promoting tumor cell metastasis. His long-term research goal is to determine whether targeting platelet–tumor cell interactions with antiplatelet medications offers a novel therapeutic approach to limit the progression of malignant disease.
Lauren G. Poole ([Fig. 5]) is an assistant professor in the Department of Pharmacology at Rutgers University Robert Wood Johnson Medical School. Her research interests focus on the role of blood coagulation factors in tissue injury, inflammation, and fibrosis. Her findings have been published in leading peer-reviewed journals in the fields of thrombosis and hemostasis, toxicology, and hepatology. Dr. Poole is also actively committed to enhancing opportunities for early career researchers by serving the ISTH as a member of the Early Career Committee and as the early career liaison to the Education Core Committee.
Azita H. Talasaz ([Fig. 6]) is one of the better-established young investigator awardees. She obtained her PharmD and PhD in clinical pharmacy in 2006 and 2011, respectively, from Tehran University and Shahid Beheshti University of Medical Sciences, Tehran, Iran. She is board certified in pharmacotherapy (2011) and cardiology (2018), and also a fellow of American College of Clinical Pharmacists (2022). In 2020, she joined VCU as a fellow in experimental cardiovascular pharmacotherapy, and then transitioned to a research faculty in 2022. She had an indispensable role in several studies on COVID-19-associated thrombotic complications: INSPIRATION and INSPIRATION-S papers published in JAMA and BMJ, two state-of-art reviews in JACC (lead author), the follow-up of INSPIRATION and a review on novel antithrombotic agents in J Thromb Haemost (lead author).
Stefano Lancellotti ([Fig. 7]) is another of the better-established young investigator awardees. He currently works as a laboratory manager at the Haemostasis and Thrombosis Center of Foundation “A. Gemelli” Hospital IRCCS of Rome in Italy. He has been working for over 10 years in the field of hemostasis and thrombosis. He earned a PhD in pathophysiology and pharmacology of hemostasis and thrombosis and, subsequently, a specialization in clinical biochemistry. His research activity has focused since the beginning on hemophilia, factor VIII, and von Willebrand factor. In recent years, he has begun to more deeply study the extrahemostatic functions of coagulation factors. Since 2021, he is the Lazio regional contact person for the Italian Society for the Study of Haemostasis and Thrombosis (SISET).
All award winners were thrilled to hear that they had been selected to receive an Eberhard F. Mammen Young Investigator award, and provided the following additional commentary:
I am very grateful and honored to be awarded an Eberhard F. Mammen Young Investigator Award. This would not be possible without the collaboration and contribution of many colleagues, but in particular I would like to thank my supervisors Prof. Dr. Suzanne Cannegieter and Prof. Dr. Henri Versteeg for their support and mentorship. A special mention to Prof. Dr. Maha Othman, who acknowledged our presented work on cancer-associated thrombosis and nominated me for this award. Lastly, a thank you to the editorial committee of Seminars in Thrombosis and Hemostasis for this recognition. This award enables me to continue my scientific career as a more independent researcher in the field of thrombosis and hemostasis and I look forward to building on this opportunity.
– Rayna Anjis ([Fig. 2])
I am truly honored to be one of the recipients of the 2022 Eberhard F. Mammen Young Investigator Award. It is a privilege to have my research recognised and I would like to sincerely thank the editorial board of Seminars in Thrombosis and Haemostasis for this recognition. None of this would have been possible without the support of my supervisor Dr Roger Preston, who I would like to thank for his mentorship and encouragement. I would also like to extend my thanks to all our collaborators and my colleagues in the Irish Centre for Vascular Biology whose input has been invaluable. I look forward to building on my research to date to further enhance our understanding of immunothrombosis.
– Aisling Rehill ([Fig. 3])
I am honored to have been nominated, considered, and selected for an Eberhard F. Mammen Young Investigator Award. Given the caliber of previous recipients and their presentations, it is truly humbling to have our work recognized in such a way and my sincerest thanks go out to the selection committee. Because our research focuses on the crosstalk between platelets and the tumor microenvironment, it is tremendously validating and motivating to know that experts in thrombosis found our ISTH presentation so compelling. Of course, this work is only made possible by having a highly supportive team and I am extremely grateful to Elisabeth Battinelli for providing unwavering mentorship throughout my post-doctoral training. This award will undoubtedly support the next steps in my career as I aim to transition into an independent investigator.
– Harvey Roweth ([Fig. 4])
It is a true honor to be selected for one of the 2022 Eberhard F. Mammen Young Investigator Awards. I would like to express my sincerest gratitude to the Seminars in Thrombosis and Hemostasis editorial board for their recognition of my work investigating abnormal fibrinogen γ-chain cross-linking in fibrinogen γΔ5 mutant mice. This work would not have been possible without the unwavering support of my postdoctoral mentor, Dr. James Luyendyk (Michigan State University), the vital contributions of our collaborators, and our support from the National Institutes of Health. I am truly honored to have my name listed alongside the current and previous winners of this award, all of whom are pioneering young investigators in thrombosis and hemostasis.
– Lauren G. Poole ([Fig. 5])
I am truly honored to have been selected for a 2022 Eberhard F. Mammen Young Investigator Award. I am grateful to my friend and mentor, Dr. Behnood Bikdeli, for all his kind and dedicated support. I would also like to express sincere appreciation to another mentor, Prof Benjamin Van Tassell, for his unwavering commitment to my training and career development. Finally, I wish to thank the selection committee and the Seminars in Thrombosis and Hemostasis editorial team for the recognition awarded to me. This award will have an invaluable impact on my career path as I continue to pursue my goal of becoming an investigator in the field of thrombosis.
– Azita H. Talasaz ([Fig. 6])
I am very grateful and extremely honoured to be awarded a 2022 Eberhard F. Mammen Young Investigator Award. This award acknowledges our research efforts on the extra-hemostatic roles that clotting factors play beyond coagulation. I am very proud because this research was born from the collaboration with a good friend, an expert scientist in the field of bone biology: Dr Andrea Del Fattore. I also want to extend my recognition to the entire team behind this project. I would like to thank my mentor, Professor Raimondo De Cristofaro, for his unwavering support, precious teachings, for his patience and for the time devoted to my growth. Finally, I would like to thank Prof Emmanuel Favaloro and the editorial board of Seminars in Thrombosis and Hemostasis for selecting me, as initially based on my oral communication at the 2022 ISTH meeting, for this prestigious recognition.
– Stefano Lancellotti ([Fig. 7])
In keeping with previous editorials, I have again updated the Young Investigator Awardees from previous years as well as the outcome of their subsequent submissions to STH, as summarized in [Table 2]. The most recent arising publications are also listed in the reference list for the benefit of the readership.[3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] I have mentioned several times my personal gratification that most of the papers from earlier years have subsequently appeared in several annual top 100 listings. Of further interest, some of these papers or the young investigators themselves have subsequently won one of the Most Popular awards (see [Table 1] for a list of prior editorials on these awards). Indeed, the manuscript by a previous Young Investigator Awardees winner, Matthias Engelen (et al),[5] was a winner in the 2023 Most Popular Articles, as recently announced.[2]
I continue to look forward to seeing the careers of the current and past Young Investigator Awardees winners developing over forthcoming years. Very high bars are now established for future Young Investigator Awardees, and I wish all awardees the best of luck to exceed the precedence set by earlier award winners.
#
Conflict of Interest
None declared.
-
References
- 1 Favaloro EJ. 2022 Eberhard F. Mammen Award Announcements: Part I - Most Popular Articles. Semin Thromb Hemost 2022; 48 (05) 502-513
- 2 Favaloro EJ. 2023 Eberhard F. Mammen Award Announcements: Part I - Most Popular Articles. Semin Thromb Hemost 2023; 49 (05) 417-426
- 3 Danese E, Montagnana M, Gelati M, Lippi G. The role of epigenetics in the regulation of hemostatic balance. Semin Thromb Hemost 2021; 47 (01) 53-62
- 4 Byrne B, Ryan K, Lavin M. Current challenges in the peripartum management of women with von Willebrand disease. Semin Thromb Hemost 2021; 47 (02) 217-228
- 5 Engelen MM, Vandenbriele C, Balthazar T. et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021; 47 (04) 362-371
- 6 Boon GJAM, Huisman MV, Klok FA. Why, whom, and how to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Semin Thromb Hemost 2021; 47 (06) 692-701
- 7 Mason GA, Rabbolini DJ. The current role of platelet function testing in clinical practice. Semin Thromb Hemost 2021; 47 (07) 843-854
- 8 Ward S, O'Sullivan JM, O'Donnell JS. The biological significance of von Willebrand factor O linked glycosylation. Semin Thromb Hemost 2021; 47 (07) 855-861
- 9 Kearney KJ, Ariëns RAS, Macrae FL. The role of fibrin(ogen) in wound healing and infection control. Semin Thromb Hemost 2022; 48 (02) 174-187
- 10 Al-Samkari H. Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians. Semin Thromb Hemost 2022; 48 (05) 514-528
- 11 Driever EG, Lisman T. Effects of inflammation on hemostasis in acutely ill patients with liver disease. Semin Thromb Hemost 2022; 48 (05) 596-606
- 12 Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023; 49 (05) 444-452
- 13 de Jong CMM, Boon GJAM, Le YNJ, Barco S, Siegerink B, Klok FA. The Post-Venous Thromboembolism Functional Status scale: from call to action to application in research, extension to COVID-19 patients and its use in clinical practice. Semin Thromb Hemost 2023; 49 (07) 764-773
Address for correspondence
Publication History
Article published online:
28 April 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Favaloro EJ. 2022 Eberhard F. Mammen Award Announcements: Part I - Most Popular Articles. Semin Thromb Hemost 2022; 48 (05) 502-513
- 2 Favaloro EJ. 2023 Eberhard F. Mammen Award Announcements: Part I - Most Popular Articles. Semin Thromb Hemost 2023; 49 (05) 417-426
- 3 Danese E, Montagnana M, Gelati M, Lippi G. The role of epigenetics in the regulation of hemostatic balance. Semin Thromb Hemost 2021; 47 (01) 53-62
- 4 Byrne B, Ryan K, Lavin M. Current challenges in the peripartum management of women with von Willebrand disease. Semin Thromb Hemost 2021; 47 (02) 217-228
- 5 Engelen MM, Vandenbriele C, Balthazar T. et al. Venous thromboembolism in patients discharged after COVID-19 hospitalization. Semin Thromb Hemost 2021; 47 (04) 362-371
- 6 Boon GJAM, Huisman MV, Klok FA. Why, whom, and how to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. Semin Thromb Hemost 2021; 47 (06) 692-701
- 7 Mason GA, Rabbolini DJ. The current role of platelet function testing in clinical practice. Semin Thromb Hemost 2021; 47 (07) 843-854
- 8 Ward S, O'Sullivan JM, O'Donnell JS. The biological significance of von Willebrand factor O linked glycosylation. Semin Thromb Hemost 2021; 47 (07) 855-861
- 9 Kearney KJ, Ariëns RAS, Macrae FL. The role of fibrin(ogen) in wound healing and infection control. Semin Thromb Hemost 2022; 48 (02) 174-187
- 10 Al-Samkari H. Systemic antiangiogenic therapies for bleeding in hereditary hemorrhagic telangiectasia: a practical, evidence-based guide for clinicians. Semin Thromb Hemost 2022; 48 (05) 514-528
- 11 Driever EG, Lisman T. Effects of inflammation on hemostasis in acutely ill patients with liver disease. Semin Thromb Hemost 2022; 48 (05) 596-606
- 12 Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023; 49 (05) 444-452
- 13 de Jong CMM, Boon GJAM, Le YNJ, Barco S, Siegerink B, Klok FA. The Post-Venous Thromboembolism Functional Status scale: from call to action to application in research, extension to COVID-19 patients and its use in clinical practice. Semin Thromb Hemost 2023; 49 (07) 764-773